-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|January 1, 2000

Supplements and Featured Publications

Optimizing Quality of Care and Cost Effectiveness in Treating Allergic Rhinitis in a Managed Care Se
Volume 6
Issue 1 Suppl

Participating Faculty

Download PDF: Participating Faculty

Articles in this issue

over 26 years ago

Article

Selected Abstracts

over 26 years ago

Article

over 26 years ago

Article

Optimizing Quality of Care and Cost Effectiveness in Treating Allergic Rhinitis in a Managed Care Setting

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC Letter to the Editor

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

AJMC original research policy

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

AJMC commentary

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

AJMC commentary

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

AJMC original research policy

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD